Gedea Biotech AB

05/09/2025

Lunds universitet sprider kunskap om hur innovation blir till patientnytta och vi är glada att kunna bidra.

Så roligt med alla reaktioner och kommentarer!

Sveda, klåda och illaluktande flytningar är både ett vanligt och ett stigmatiserat tillstånd som kan bero på en obalans i vaginans bakterieflora, svamp eller bådadera. Bakteriell vaginos, eller slidkatarr som tillståndet också kallas, behandlas idag med antibiotika alternativt antiseptiska l...

05/09/2025

Sydsvenskan har gjort ett jättefint reportage om innovationen och forskarna bakom pHyph, Gedeas behandling mot bakteriell vaginos.

Gedea är just nu inne i aktiva diskussioner med flera läkemedelsföretag som är intresserade av att marknadsföra och sälja pHyph i olika länder i Europa. Vi hoppas att kunna lansera pHyph på de första marknaderna under 2026.

Följ oss genom att prenumerera på nyhetsbrev https://gedeabiotech.se/nyheter/

https://www.sydsvenskan.se/artikel/nytt-piller-botar-infektioner-i-vaginan-lundaforskare-bakom-metoden/

Minskar behovet av antibiotika • Boostar de goda bakterierna.

05/09/2025

pHyph är godkänt för behandling av bakteriell vaginos och för att stärka det vaginala mikrobiomet. I den här intervjun i Sveriges Radio P3 förklarar dr. Helena Strevens hur det fungerar:

Ett nytt piller mot bakteriell vaginos, en sjukdom som drabbar var fjärde kvinna varje år, kan snart vara ute på marknaden.I dag behandlas besvären med ...

05/09/2025

pHyph is an antibiotic-free vaginal tablet designed to both treat BV and promote a healthy vaginal microbiome. pHyph has now been approved for treatment of bacterial vaginosis in the EU.

Gedea Biotech’s lead product pHyph has received CE-marking under the EU Medical Device Regulation (MDR) for the treatment of bacterial vaginosis (BV).

The approval confirms the efficacy and safety of pHyph and opens up a large market opportunity in Europe. The novel, antibiotic free mode of action will improve treatment of bacterial vaginosis for millions of women and reduce use of antibiotics, and our ambition is to make pHyph available in pharmacies in the first markets in 2026, says Annette Säfholm, CEO of Gedea Biotech.

Bacterial vaginosis affects one in three women. While current treatments rely on antibiotics, pHyph offers a modern solution. It’s a vaginal tablet that restores the natural environment by lowering pH and promoting beneficial lactobacilli, treating the infection while also strengthening the natural microbiome to reduce the risk for future recurrence.

With its active ingredient already approved as a food additive, pHyph is safe and effective. Clinical studies show that it provides symptom relief from day one.

We are working woith leading medical companies in Europe to launch pHyph on the first markets in 2026. Sign up for our newspaper and we will keep ypo posted. https://gedeabiotech.com/news/

10/03/2025

On the International Women's Day we want to address the THE WOMEN’S HEALTH GAP
Research in women’s health primarily focuses on diseases with high mortality, overlooking diseases leading to disability. Many gynecological conditions are neglected because research and investment focuses on saving lives rather than adding healthy years to lives. As pointed out in the report by McKinsey Health Institute: “In all, when tackling women’s health, the solution is not to divide more slices of one pie: it’s to make more pie.”

At Gedea Biotech AB, we know that many women spend years, literally, with recurring vaginal infections and even more time worrying about the next episode of BV or fungal infection. Our aim is to decrease years spent with debilitating gynecological conditions.

Source: Closing the women’s health gap: A $1 trillion opportunity to improve lives and economies by McKinsey Health Institute and World Economic Forum

https://www.mckinsey.com/mhi/our-insights/closing-the-womens-health-gap-a-1-trillion-dollar-opportunity-to-improve-lives-and-economies

16/10/2024

Today Eva Norell from Gedea Biotech AB attended the Nordic-African Women’s Health conference Organized by the Women African Ambassadors in Sweden, Ferring Pharmaceuticals and United Nations Population Fund (UNFPA) at the Ferring headquarters in Copehagen. Topics for the day was innovation in women’s health and antimicrobial resistance.

Antimicrobial resistance hits all parts of society; health care, agriculture, economic. There are no s*x differentiated data on how AMR hits but women are like to receive antibiotics 27% more often than men, during life. AMR is projected to surpass cancer as the leading cause of death, by 2025.

Thank you for the invite to this eye opening event, we are inspired to make a sustainable contribution to women’s health, globally.

16/10/2024

I "Vetenskapsradion På Djupet" berättar Luisa Hugerth vid Uppsala universitet hur forskning om de bakterier som bor i kroppen kan hjälpa oss att lindra besvär i underlivet. I programmet slår man ihjäl några myter om underlivshälsa och förmedlar intressant och användbar kunskap om bland annat bakteriell vaginos.

Louisa Hugerth är biträdande handledare till Gedeas industridoktorand Emilia Lahtinen vid Karolinska Institutet, vid sidan av handledare Ina Schuppe Koistinen.

Nyttan av att ha en blandning av goda bakterier i tarmen har uppmärksammats mycket de senaste åren. Men nu klarnar också bilden alltmer om hur bakterier ...